MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Merus NV

Fechado

SetorSaúde

42.89 8.91

Visão Geral

Variação de preço das ações

24h

Atual

Mín

38.1

Máximo

43.22

Indicadores-chave

By Trading Economics

Rendimento

69M

-31M

Vendas

-2.6M

9.1M

EPS

-0.49

Margem de lucro

-338.326

Funcionários

260

EBITDA

8.2M

-88M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+125.53% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-119M

3.1B

Abertura anterior

33.98

Fecho anterior

42.89

Sentimento de Notícias

By Acuity

25%

75%

66 / 386 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Merus NV Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

2 de abr. de 2025, 23:55 UTC

Ações em Alta

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2 de abr. de 2025, 22:50 UTC

Grandes Movimentos do Mercado

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2 de abr. de 2025, 21:08 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2 de abr. de 2025, 21:00 UTC

Ganhos

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2 de abr. de 2025, 23:56 UTC

Conversa de Mercado

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:44 UTC

Conversa de Mercado

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2 de abr. de 2025, 23:44 UTC

Principais Notícias

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 23:32 UTC

Conversa de Mercado

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

2 de abr. de 2025, 23:12 UTC

Conversa de Mercado

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2 de abr. de 2025, 23:10 UTC

Conversa de Mercado

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2 de abr. de 2025, 23:09 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:57 UTC

Conversa de Mercado

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 22:56 UTC

Conversa de Mercado

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2 de abr. de 2025, 22:43 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2 de abr. de 2025, 22:12 UTC

Conversa de Mercado

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2 de abr. de 2025, 21:48 UTC

Principais Notícias

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2 de abr. de 2025, 21:41 UTC

Conversa de Mercado

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 de abr. de 2025, 21:17 UTC

Conversa de Mercado

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2 de abr. de 2025, 21:04 UTC

Principais Notícias

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2 de abr. de 2025, 21:03 UTC

Conversa de Mercado

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2 de abr. de 2025, 20:53 UTC

Ganhos

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2 de abr. de 2025, 20:52 UTC

Ganhos

Kaiser Aluminum Changes Inventory Acctg Methodology

Comparação entre Pares

Variação de preço

Merus NV Previsão

Preço-alvo

By TipRanks

125.53% parte superior

Previsão para 12 meses

Média 89.31 USD  125.53%

Máximo 110 USD

Mínimo 67 USD

Com base em 15 analistas de Wall Street que oferecem metas de preço de 12 meses para Merus NV - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

15 ratings

15

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

39 / 47Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Neutral Evidence

Longo Prazo

Weak Bearish Evidence

Sentimento

By Acuity

66 / 386 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Merus NV

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.